BR0014563A - Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica - Google Patents

Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica

Info

Publication number
BR0014563A
BR0014563A BR0014563-7A BR0014563A BR0014563A BR 0014563 A BR0014563 A BR 0014563A BR 0014563 A BR0014563 A BR 0014563A BR 0014563 A BR0014563 A BR 0014563A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
product
growth factor
anabolic
growth factors
Prior art date
Application number
BR0014563-7A
Other languages
English (en)
Inventor
Maarten Anne Hoijer
Robert Johan Joseph Hageman
Rudolf Leonardus Lodewi Smeets
Original Assignee
Nutricia Nv
Campina Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv, Campina Bv filed Critical Nutricia Nv
Publication of BR0014563A publication Critical patent/BR0014563A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE FATOR DE CRESCIMENTO DE TRANSFORMAçãO BETA E FATORES DE CRESCIMENTO ANABóLICO, PRODUTO, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se ao uso de fator de crescimento de transformação <225> (TGF-<225>) e fatores de crescimento anabólico (AGF) no tratamento e/ou prevenção de mau funcionamento ou doença da mucosa intestinal. Mais particularmente, a invenção refere-se ao tratamento e/ou prevenção de dano da mucosa intestinal como resultado de quimioterapia ou radioterapia ou de doenças inflamatórias do intestino com um produto compreendendo: a) uma primeira composição farmacêutica compreendendo TGF-<225> obtido por extração de um produto lácteo de mamífero na ausência substancial de fator de crescimento semelhante a insulina 1 (IGF-1), b) uma segunda composição farmacêutica compreendendo AGF na ausência substancial de TGF-<225>; em que a primeira e segunda composição são administradas seq³encialmente.
BR0014563-7A 1999-10-06 2000-10-06 Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica BR0014563A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL1999/000620 WO2001024812A1 (en) 1999-10-06 1999-10-06 USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
PCT/NL2000/000719 WO2001024813A1 (en) 1999-10-06 2000-10-06 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Publications (1)

Publication Number Publication Date
BR0014563A true BR0014563A (pt) 2002-06-11

Family

ID=19866617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014563-7A BR0014563A (pt) 1999-10-06 2000-10-06 Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica

Country Status (6)

Country Link
EP (2) EP1221965A1 (pt)
JP (1) JP2003510367A (pt)
CN (2) CN1378458A (pt)
AU (2) AU6232899A (pt)
BR (1) BR0014563A (pt)
WO (2) WO2001024812A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928186A1 (de) * 1989-08-25 1991-03-14 Niehoff Kg Maschf Greifvorrichtung fuer drahtspulen und dergleichen
FR2827290B1 (fr) 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
GB0229658D0 (en) * 2002-12-20 2003-01-22 Cleeve Richard J Bird feed
TWI356681B (en) * 2003-11-12 2012-01-21 J Oil Mills Inc Body taste improver comprising long-chain highly u
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US7744895B2 (en) * 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
CN101505781A (zh) * 2006-06-22 2009-08-12 阿根尼克斯有限公司 作为辐射防护物质的乳铁蛋白
US8350006B2 (en) 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
US8986769B2 (en) 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US8367354B2 (en) 2008-10-24 2013-02-05 Mead Johnson Nutrition Company Methods for determining the levels of TGF-β in a composition
SG10201704531XA (en) * 2008-12-08 2017-07-28 Soligenix Inc Topically active steroids for use in radiation and chemotherapeutics injury
JP5552386B2 (ja) * 2010-07-09 2014-07-16 株式会社ファンケル Ｌ−アスコルビン酸−２−リン酸−６−脂肪酸凍結乾燥製剤及び化粧料
US20120171328A1 (en) 2011-01-05 2012-07-05 Dattatreya Banavara Composition comprising heat labile milk proteins and process for preparing same
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
PL423673A1 (pl) * 2017-12-01 2019-06-03 Lewandowska Agata Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
CN110051698A (zh) * 2019-03-18 2019-07-26 天津大学 基于微囊化处理的肠道原生菌基因改造的方法
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
MX2022001065A (es) 2019-07-30 2022-02-14 Shanghai Hansoh Biomedical Co Ltd Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2023524875A (ja) 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
CN116472049A (zh) 2020-06-30 2023-07-21 特尼奥生物股份有限公司 与bcma结合的多特异性抗体
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
CN118020946A (zh) * 2024-03-06 2024-05-14 美赞臣婴幼儿营养品技术(广州)有限公司 保护肠道屏障和/或预防中枢神经系统疾病的营养组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3206784C2 (de) * 1982-02-25 1985-05-09 Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation
EP0269408A3 (en) * 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US5451411A (en) * 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
DE69506095T2 (de) * 1995-08-04 1999-06-24 Naamloze Vennootschap Nutricia, Zoetermeer Diätfasern enthaltende Nahrungszusammensetzung
EP0852913A1 (en) * 1997-01-14 1998-07-15 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
NL1005677C2 (nl) * 1997-03-27 1998-09-29 Campina Melkunie Bv Werkwijze voor het winnen van groeifactoren, of een samenstelling die één of meer groeifactoren bevat, uit melk of een derivaat daarvan.
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung

Also Published As

Publication number Publication date
WO2001024813A1 (en) 2001-04-12
AU1063201A (en) 2001-05-10
JP2003510367A (ja) 2003-03-18
CN1626239A (zh) 2005-06-15
CN1378458A (zh) 2002-11-06
EP1221965A1 (en) 2002-07-17
WO2001024812A1 (en) 2001-04-12
CN1299766C (zh) 2007-02-14
EP1779863A1 (en) 2007-05-02
AU6232899A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
BR0014563A (pt) Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica
Kotzampassi et al. A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study
DE3263573D1 (en) Pharmaceutically active phenylcarboxylic acid derivatives
BG101118A (en) Therapeutical compounds
Tang et al. Effects of orally administering the antimicrobial peptide buforin II on small intestinal mucosal membrane integrity, the expression of tight junction proteins and protective factors in weaned piglets challenged by enterotoxigenic Escherichia coli
Kelsey et al. Presence of azithromycin breast milk concentrations: a case report
SE9704693L (sv) Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
KR20030092082A (ko) 활성 성분으로 조효소 ｑ를 함유하는 경점막 투여용 조성물
US6025400A (en) Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same
US10022394B2 (en) Antiinfective composition
Williams Non-antimicrobial activities of macrolides
CN120114574B (zh) 重组iii型人源化胶原蛋白在胃癌产品中的新用途
CA3199000A1 (en) Composition containing 1,8-cineole for therapeutic use
AU4155700A (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
CN116617361A (zh) 百里香酚在制备mcr-1酶抑制剂中的应用
Midtvedt et al. Influence of antibiotics on microbial intestinal transformation of cholesterol to coprostanol in man
Wu et al. Burdock essence promotes gastrointestinal mucosal repair in ulcer patients
PT1510214E (pt) 8a¿azalidos como agentes antimicrobianos veterinários
CN105055313B (zh) 一种畜禽使用的复方磺胺类纳米乳制剂及其制备方法
KR20200037523A (ko) 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물
US8668908B2 (en) Method for alleviating chemotherapy side effects using extract of Dioscorea sp
EP0443957A3 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
CN101829129A (zh) 兽用复方硫酸庆大霉素注射液及其制备方法
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
CN106389454A (zh) 一种兽用复方硫氰酸红霉素可溶性粉及其制备方法

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/18 (2006.01), A61K 36/899 (2006.01), A61K